JP2017500320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500320A5 JP2017500320A5 JP2016540552A JP2016540552A JP2017500320A5 JP 2017500320 A5 JP2017500320 A5 JP 2017500320A5 JP 2016540552 A JP2016540552 A JP 2016540552A JP 2016540552 A JP2016540552 A JP 2016540552A JP 2017500320 A5 JP2017500320 A5 JP 2017500320A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- cas number
- delta
- intellikine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919625P | 2013-12-20 | 2013-12-20 | |
| US61/919,625 | 2013-12-20 | ||
| PCT/US2014/071724 WO2015095825A1 (en) | 2013-12-20 | 2014-12-19 | Cancer treatments using combinations of type 2 mek and erk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500320A JP2017500320A (ja) | 2017-01-05 |
| JP2017500320A5 true JP2017500320A5 (OSRAM) | 2018-02-08 |
| JP6678583B2 JP6678583B2 (ja) | 2020-04-22 |
Family
ID=53403790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540552A Active JP6678583B2 (ja) | 2013-12-20 | 2014-12-19 | ２型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを用いるがん処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11007184B2 (OSRAM) |
| EP (3) | EP3984537B1 (OSRAM) |
| JP (1) | JP6678583B2 (OSRAM) |
| AU (1) | AU2014368912B2 (OSRAM) |
| ES (2) | ES2953311T3 (OSRAM) |
| WO (1) | WO2015095825A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2240451T3 (da) | 2008-01-04 | 2017-11-20 | Intellikine Llc | Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| PE20180318A1 (es) | 2011-01-10 | 2018-02-09 | Infinity Pharmaceuticals Inc | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| LT2914296T (lt) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| UA125216C2 (uk) | 2016-06-24 | 2022-02-02 | Інфініті Фармасьютікалз, Інк. | Комбінована терапія |
| US11401553B2 (en) | 2016-08-31 | 2022-08-02 | The Children's Hospital Of Philadelphia | Compositions and methods for the diagnosis and treatment of lymphatic system disorders |
| WO2018146253A1 (en) * | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| CN110799245B (zh) * | 2017-05-16 | 2022-08-09 | 生物医学谷探索股份有限公司 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
| US11406605B2 (en) * | 2017-12-20 | 2022-08-09 | Golden Biotechnology Corporation | Therapeutic compositions for treating pancreatic cancer |
| WO2019139970A1 (en) * | 2018-01-09 | 2019-07-18 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
| EP4087840A4 (en) | 2020-01-10 | 2024-01-10 | Immuneering Corporation | MEK INHIBITORS AND THEIR THERAPEUTIC USES |
| US11084780B1 (en) | 2021-02-17 | 2021-08-10 | Springworks Therapeutics, Inc. | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11066358B1 (en) | 2021-02-17 | 2021-07-20 | Warner-Lambert Company Llc | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| EP0689610B1 (en) | 1993-03-19 | 2002-07-03 | Sequenom, Inc. | Dna sequencing by mass spectrometry via exonuclease degradation |
| US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| GB0320059D0 (en) | 2003-08-27 | 2003-10-01 | Solexa Ltd | A method of sequencing |
| EP3305776B1 (en) * | 2004-05-14 | 2019-09-25 | Vertex Pharmaceuticals Incorporated | Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
| TW200829234A (en) * | 2007-01-08 | 2008-07-16 | Golden Biotechnology Corp | Antrodia camphorata isophorone extract |
| KR20100025553A (ko) * | 2007-06-05 | 2010-03-09 | 쉐링 코포레이션 | 암 치료용 ｅｒｋ 억제제로서의 폴리사이클릭 인다졸 유도체 및 이의 용도 |
| WO2010062546A1 (en) | 2008-10-27 | 2010-06-03 | Qiagen Gaithersburg Inc. | Fast results hybrid capture assay on an automated platform |
| KR20120046018A (ko) | 2010-10-04 | 2012-05-09 | 삼성테크윈 주식회사 | 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출 |
| US20130217721A1 (en) * | 2010-11-19 | 2013-08-22 | The Regents Of The University Of California | Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US20130023531A1 (en) * | 2011-01-27 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| US20150166646A1 (en) * | 2012-06-15 | 2015-06-18 | The Wistar Institute Of Anatomy And Biology | Methods and Compositions for Treating or Diagnosing Melanoma |
-
2014
- 2014-12-19 JP JP2016540552A patent/JP6678583B2/ja active Active
- 2014-12-19 ES ES14871217T patent/ES2953311T3/es active Active
- 2014-12-19 US US15/105,871 patent/US11007184B2/en active Active
- 2014-12-19 EP EP21193832.9A patent/EP3984537B1/en active Active
- 2014-12-19 EP EP24164571.2A patent/EP4389225A3/en active Pending
- 2014-12-19 ES ES21193832T patent/ES2986019T3/es active Active
- 2014-12-19 AU AU2014368912A patent/AU2014368912B2/en active Active
- 2014-12-19 EP EP14871217.7A patent/EP3082779B1/en active Active
- 2014-12-19 WO PCT/US2014/071724 patent/WO2015095825A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500320A5 (OSRAM) | ||
| JP2017502017A5 (OSRAM) | ||
| JP2017502013A5 (OSRAM) | ||
| JP2017502016A5 (OSRAM) | ||
| Leonard et al. | AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma | |
| Tahara et al. | Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) | |
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| Zarogoulidis et al. | mTOR pathway: A current, up-to-date mini-review | |
| Galizia et al. | Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer | |
| JP7405408B2 (ja) | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 | |
| Fazio et al. | A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours | |
| Beuselinck et al. | Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases | |
| Budde et al. | Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received≥ 2 prior lines of therapy: pivotal results from a phase I/II study | |
| O’Sullivan | Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors | |
| JP2020519660A5 (OSRAM) | ||
| JP2017502014A5 (OSRAM) | ||
| CA2407466A1 (en) | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype | |
| Oudard et al. | Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study | |
| KR20140036193A (ko) | 아플리버셉트, 폴린산, 5-플루오로우라실(5-fu) 및 이리노세탄(folfiri)을 포함하는 조성물 | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| Bracarda et al. | Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY) | |
| Yoon et al. | Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib | |
| JP2018519324A5 (OSRAM) | ||
| Besse et al. | A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer |